Objective: To observe the clinical efficacy of paclitaxel combined with radiotherapy in the treatment of advanced breast cancer and evaluate the safety.Methods: 74 patients with advanced breast cancer were chosen and randomly divided into the observation group and the control group, 37 cases in each group. The observation group wastreated with paclitaxel chemotherapy combined with radiotherapywhile the control group was treated with radiotherapy treatment for a total of 2 courses of treatment, with the improvement of life quality, expression levels of the tissue in patients with Bax and p53 mRNA , clinical efficacy and incidence of adverse reactions compared.Results: After treatment, the total efficiency rate of the observation group is higher than that of the control group (χ2=7.929, P=0.005); the improvement rate of life quality in the observation group (62.2 %) was higher than that of the control group (18.9 %) (χ2=14.352, P=0.000).Before treatment, there was no difference in the expression levels of Bax and p53 mRNA in breast tissue of the two groups (P＞0.05). After treatment, the two expression levels were increased (P＜0.05), and the expression levels of Bax and p53 mRNA in the observation group were higher than those of the control group (P＜0.05); the incidence rates of adverse reaction in the observation group and the control group were 13.51% (5/ 37) and 16.22 % (6/37) respectively, there being no difference(χ2=0.107,P=0.743).Conclusion: Paclitaxel concurrent radiotherapy and chemotherapy can improve the therapeutic efficacy for patients with advanced breast cancer, improve the quality of life and the expression levels of Bax and p53 in breast tissueand have less adverse reactions, worthy of popularization and application.
HU Donghao
. Clinical efficacy of paclitaxel combined with radiotherapy in the treatment of advanced breast cancer and safety evaluation[J]. Journal of Baotou Medical College, 2017
, 33(9)
: 11
-13
.
DOI: 10.16833/j.cnki.jbmc.2017.09.005
[1] 郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-569.
[2] 郑巧,崔飞飞,卢雯平,等.疏肝益肾方加减联合放化疗对三阴乳腺癌患者免疫调控及生活质量的影响[J].中医杂志,2015,56(20):1742-1745.
[3] Xiea Y,Wangb R.Pttg1 Promotes Growth of Breast Cancer through P27 Nuclear Exclusion[J].Cell Physiol Biochem,2016,38(1):393-400.
[4] 黄维,董嘉尧,周成宇,等.紫杉醇同步放化疗在中晚期乳腺癌细胞增殖抑制中的作用及并发症预防对策[J].海南医学院学报,2016,22(14):1594-1597.
[5] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[6] 左婷婷,陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床,2016,43(14):639-642.
[7] Couderc C,Boin A,Fuhrmann L,et al.AMOTL1 promotes breast cancer progression and is antagonized by merlin[J].Neoplasia,2016,18(1):10-24.
[8] 李莉,王建军.乳腺癌保乳后同步放化疗对患者机体免疫力的影响[J].中国普外科手术学杂志(电子版),2015,9(6):20-22.
[9] 姚煊,赵玲,李索妮,等.紫杉醇脂质体对乳腺癌细胞SK-BR-3的放疗增敏作用及其机制[J].西安交通大学学报(医学版),2015,36(9):628-632.
[10] 陈思颖,蔡江霞,张蔚鹏,等.紫杉醇诱导的乳腺癌耐药细胞的蛋白质组学研究[J].中国药学杂志,2014,32(10):825-832.
[11] Yu L,Ma J,Han J,et al.Licochalcone B arrests cell cycle progression and induces apoptosis in human breast cancer MCF-7 cells[J].Recent Pat Anticancer Drug Discov,2016,11(4):444-452.
[12] Shrestha M,Park PH.p53 signaling is involved in leptin-induced growth of hepatic and breast cancer cells[J].Korean J Physiol Pharmacol,2016,20(5):487-498.
